Coronavirus: SARS-CoV-2 (COVID-19) Program

It is believed that nitric oxide may inhibit viral replication through formation of reactive intermediates that alter the function of viral proteins in infected cells.1 We are exploring the potential of our NITRICIL™ technology as a potential treatment option for COVID-19 and are conducting in vitro assessments targeting the reduction of viral burden and transmission.

Program Highlights

Results from in vitro assessment of concentrations as low as 0.75 mg/mL demonstrated berdazimer sodium reduced 90% of virus after repeat dosing, once daily

First demonstration of antiviral effect of NO-based medicine against SARS-CoV-2 in an in vitro model that mimics the human airway epithelium

Engaged Catalent, a global leader in providing integrated services, superior delivery technologies and manufacturing solutions, to develop an intranasal formulation of berdazimer sodium

Upon positive pre-clinical studies, explore potential strategic partners

Learn About Nitric Oxide NITRICIL™


Coronaviridae is a family of single-stranded, positive RNA viruses. Members of this family include coronaviruses associated with the common cold that are capable of causing mild respiratory and enteric infections in humans and other vertebrate animals. Some coronaviruses are also known to cause severe infections and diseases such as SARS (severe acute respiratory syndrome) and the current global pandemic of COVID-19, which is specifically caused by the SARS-CoV-2 virus.

1. Adusumilli, N. et al. “Harnessing nitric oxide for preventing, limiting and treating the severe pulmonary consequences of COVID-19”, Nitric Oxide, Volume 103, 1 October 2020, Pages 4-8; Available online 15 July 2020